Drug intelligence / Profile preview

tarlatamab + temozolomide

Development stage: Unknown
Lead developer: Amgen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Tarlatamab + temozolomide is an investigational combination therapy being evaluated for the treatment of DLL3-positive high-grade central nervous system (CNS) tumors, including high-grade gliomas. Tarlatamab is a bispecific T-cell engager (BiTE) designed to bind to Delta-like ligand 3 (DLL3) on tumor cells and CD3 on T-cells, facilitating T-cell-mediated tumor cell lysis. Temozolomide is an oral alkylating agent that induces DNA damage by methylating guanine residues. This combination, studied in the TARLATEM trial sponsored by Centre Leon Berard in collaboration with Amgen, aims to leverage the immunotherapeutic activity of tarlatamab alongside the cytotoxic effects of metronomic temozolomide in patients with high-grade brain tumors.

Brand names: ImdelltraTemodarTemodal
Other names: AMG-757AMG757AMG 757TemozolomideMetronomic temozolomideTARLATEM

Targets

CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)DNA

Beyond the preview

Go deeper on tarlatamab + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tarlatamab + temozolomide.

Explore the full profile